Search | Clinical Trials Finder

Conditions: Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Interventions: Pembrolizumab, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 738 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 23
States / cities: Los Angeles, California • Monterey, California • Orange, California + 19 more

Conditions: Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions: PF-07934040, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, Sasanlimab; Drug · Combination Product
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 26
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more

Conditions: Carcinoma, Squamous Cell of Head and Neck
Interventions: AZD1775, Cisplatin, Intensity Modulated Radiotherapy Treatments; Drug · Radiation
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions: HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30, MDADI-HN, COST-FACIT, Intensity-Modulated Radiation Therapy (Arm A), Chemoradiation (Arm B); Diagnostic Test · Behavioral · Radiation + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Non-small Cell Lung Cancer
Interventions: gemcitabine, docetaxel, cisplatin, etoposide, radiation therapy; Drug · Radiation
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 10
States / cities: Denver, Colorado • South Bend, Indiana • Baltimore, Maryland + 7 more

Conditions: Head and Neck Cancer
Interventions: Radiotherapy, Leucovorin, Cetuximab, Filgrastim, Erythropoetin, Cisplatin, Fluorouracil, Docetaxel; Radiation · Drug · Biological
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer
Interventions: Cisplatin, Carboplatin, Paclitaxel, Radiation Therapy; Drug · Radiation
Lead sponsor: Women's Cancer Care Associates, LLC; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 6
States / cities: Baltimore, Maryland • Traverse City, Michigan • Morristown, New Jersey + 3 more

Conditions: Malignant Pleural Mesothelioma, Mesothelioma
Interventions: Cisplatin, Methotrexate, Gemcitabine, Lung Cancer Symptom Scale for Mesothelioma Questionnaire; Drug · Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: pembrolizumab/vibostolimab, durvalumab, cisplatin, pemetrexed, etoposide, carboplatin, paclitaxel, thoracic radiotherapy; Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 21
States / cities: Long Beach, California • Los Angeles, California • Hollywood, Florida + 18 more

Conditions: Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer
Interventions: Cisplatin, Postoperative radiotherapy; Drug · Radiation
Lead sponsor: Lisette Nixon; Government
Eligibility: 18 Years and older
Enrollment: 1,269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 3
States / cities: Redwood City, California • Orlando, Florida • Houston, Texas

Conditions: Cervical Cancer
Interventions: Topotecan, Cisplatin, Bevacizumab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 3
States / cities: St Louis, Missouri • Durham, North Carolina • Columbus, Ohio

Conditions: Esophageal Cancer
Interventions: cetuximab, ECF, IC, FOLFOX; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 227
States / cities: Norwalk, Connecticut • Lewes, Delaware • Newark, Delaware + 158 more

Conditions: HPV-Related Squamous Cell Carcinoma, HNSCC
Interventions: nab-paclitaxel, Carboplatin, Nivolumab, Cisplatin, Hydroxyurea, 5-FU, Dexamethasone, Famotidine, Diphenhydramine, Paclitaxel, Transoral robotic surgery (TORS), Adjuvant RT, Chemoradiotherapy; Drug · Procedure · Radiation
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lung Cancer
Interventions: cisplatin, irinotecan hydrochloride, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 49
States / cities: Birmingham, Alabama • Burbank, California • Hayward, California + 39 more

Conditions: Neoplasms, Head and Neck
Interventions: Lapatinib oral tablets, radiotherapy, cisplatin chemotherapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Kansas City, Missouri • Charlotte, North Carolina

Conditions: Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
Interventions: Botensilimab, Balstilimab, Chloroquine Phosphate, Celecoxib, Nab paclitaxel, Gemcitabine, Cisplatin; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin, Cisplatin, 5-fluorouracil, Paclitaxel, Docetaxel; Combination Product · Biological · Drug
Lead sponsor: Rakuten Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 8
States / cities: Duarte, California • Miami, Florida • Tampa, Florida + 5 more

Conditions: Advanced Solid Tumors
Interventions: M3814 100 mg, M3814 200 mg, M3814 300 mg, M3814 400 mg, M3814 50 mg, Fractionated RT, Cisplatin; Drug · Radiation
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 9
States / cities: Fresno, California • Fort Lauderdale, Florida • Miami, Florida + 6 more

Conditions: Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions: PF-07985045, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, Sasanlimab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, PF-07284892; Drug · Combination Product
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 12
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more

Conditions: Uterine Cervical Neoplasms
Interventions: Pembrolizumab, Placebo for pembrolizumab, Cisplatin, External Beam Radiotherapy (EBRT), Brachytherapy; Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,060 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 28
States / cities: Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 25 more

Conditions: Non Small Cell Lung Cancer, Small Cell Lung Cancer, Thymoma, Thymus Neoplasms
Interventions: Esophageal sparing IMRT; Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions: Cisplatin-based Radiation Therapy, Cisplatin Chemotherapy; Radiation · Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 4
States / cities: Beverly Hills, California • Los Angeles, California • Tarzana, California + 1 more

Conditions: Esophageal Cancer
Interventions: bevacizumab, cisplatin, irinotecan hydrochloride, proteomic profiling, diagnostic laboratory biomarker analysis, mass spectrometry, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy; Biological · Drug · Genetic + 3 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-Small Cell Lung Cancer
Interventions: Radiation Therapy (RT), Cisplatin, Etoposide, Nivolumab, Placebo; Radiation · Drug · Other
Lead sponsor: RTOG Foundation, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 16
States / cities: La Jolla, California • Stanford, California • Gainesville, Florida + 13 more

Search by objective public record fields.

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)

Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer

Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)

Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer

Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer

Chemotherapy Combined With Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer

The Seven Trial: Exploiting the Unfolded Protein Response

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies

Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer

Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer

Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC